Trial Profile
Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary) ; Desloratadine (Primary) ; Mometasone (Primary) ; Olopatadine (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis; Conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors ALK-Abello
- 27 Feb 2023 Results assessing the Onset of clinicaleffect was evaluated for grass, ragweed, tree, and house dust mite (HDM)sublingual immunotherapy (SLIT)-tablets from NCT00227279, NCT00783198 and EudraCT2015-004821-15 studies, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 27 Apr 2021 Results of pooled analysis from three trials (2 phase-II/1 phase-III) published in the Allergy
- 07 Jun 2019 According to ALK Abello media release, the company received european approval for tree pollen sublingual allergy immunotherapy (SLIT) tablet against allergic rhinitis.